North America Opioid market cover

North America Opioid Market by Products (Codeine, Extended-release/Long-acting, Immediate-release/Short-acting, Oxycodone, Hydrocodone, Morphine, Fentanyl, Hydroxymorphone, Propoxyphene, Oxymorphone, Methadone, Buprenorphine, and Tapentadol), Applications (Cancer Pain, Pain Relief, Post-operative Pain Management, Orthopedic, Low Back Pain, Anesthesia, Fibromyalgia, Neuropathic Pain, Cough Suppression, De-addiction, and Diarrhoea Suppression), and Geography (The US & Canada) - Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: MC-2409
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 195
  • Format:
  • Pub. Date: Upcoming
  • Share:

The North America opioid market size is projected to expand at a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing geriatric population and wide popularity of pain management therapies in the region.

North America Opioid market summary

Opioids refers to a class of drugs that are widely adopted as pain relievers including anesthesia. The drugs are largely available with medical prescription such as hydrocodone, oxycodone, morphine, codeine and many others. Along with the use as analgesics, the opioids are largely used as anti-diarrheal medicines and cough suppressants. Pain relief medicines are influenced by the non-opioid, as they avoid the risk of developed drug reliance.

Meanwhile, nonsteroidal anti-inflammatory drugs fail to relieve pain when used for a long term as these drugs are distinguished by ceiling effect. Narcotics are prioritized over nonsteroidal as a result. Anti-inflammatory drugs are widely used for long-term treatment of pain management. Affordable Care Act program in 2010 declared that healthcare reforms were launched in the US to convince huge attention and increased funding, to address problems around effective pain management. Several factors such as increasing managed training of healthcare professionals and improved infrastructure for pain management play key roles for the advancement of the market growth.

Market Trends, Drivers, Restraints, and Opportunities

  • Growing number of the geriatric population who are at risk of developing irreversible and incurable situations is fueling the demand for pain management therapies. This is expected to boost the market growth.
  • Rising use of opioid medication for several pain management drugs is a critical element driving the market growth.
  • Rising penetration of generics along with the increasing healthcare investment phases in the region is estimated to spur the overall market revenue during the forecast period
  • Presence of strong drug array with efficacious and improved therapeutic drugs are anticipated to further propel the market expansion.
  • Increasing funding rate to address problems around effective pain management and other R&D activities with supportive government policies are expected to accelerate the market growth.
  • Misuse of the drugs and issues concerning to drugs abuse are key challenges that can restrict the market growth in the coming years.

Scope of the Report                         

The report on the North America opioid market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes                                         

Details

Report Title

North America Opioid Market - Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020             

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Products (Codeine, Extended-release/Long-acting, Immediate-release/Short-acting, Oxycodone, Hydrocodone, Morphine, Fentanyl, Hydroxymorphone, Propoxyphene, Oxymorphone, Methadone, Buprenorphine, and Tapentadol) and Applications (Cancer Pain, Pain Relief, Post-operative Pain Management,  Orthopedic, Low Back Pain, Anesthesia, Fibromyalgia, Neuropathic Pain, Cough Suppression,  De-addiction, and Diarrhoea Suppression)

Geographical Scope

The US & Canada

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Allergan Plc (Actavis); Purdue Pharma L.P.; Pfizer, Inc.; Egalet Corp.; and Janssen Pharmaceuticals, Inc.

Market Segment Insights

Oxymorphone segment is expected to grow at a robust pace

Based on products, the North America opioid market is classified into codeine, extended-release/long-acting, immediate-release/short-acting, oxycodone, hydrocodone, morphine, fentanyl, hydroxymorphone, propoxyphene, oxymorphone, methadone, buprenorphine, and tapentado. The oxymorphone segment accounted for a key share of the market in 2019 and is expected to grow at a robust pace during the projected period due to presence of a strong drug pipeline. However, the codeine segment is anticipated to expand at a healthy growth rate during the forecast period owing to the increasing cases of drug abuse involving drugs.

North America Opioid market product

Anesthesia segment is projected to expand at a considerable CAGR

On the basis of applications, the market is divided into cancer pain, pain relief, post-operative pain management, orthopedic, low back pain, anesthesia, fibromyalgia, neuropathic pain, cough suppression, de-addiction, and diarrhea suppression. The anesthesia segment is projected to expand at a considerable CAGR during the forecast period due to large adoption rate and growing awareness among patients. On the other hand, the cancer pain segment is anticipated to expand at substantial growth during the forecast period owing to presence of cancer pain specific drugs and burgeoning incidence rates of cancer.

The US is anticipated to constitute a key market share

In terms of geography, the North America opioid market is classified as the US and Canada. The US held a dominant market share in 2019 and is anticipated to constitute a key share of the market during the projected period due to the surging elderly population with a higher prevalence of chronic conditions. Moreover, the wide adoption of advanced techniques for drug development and discovery through extensive research funding present another key driver of the market growth in the country. Meanwhile, the market of Canada is anticipated to exhibit moderate growth during the forecast period owing to the issues related to illegal sales of opioid including OTC products in the country.

North America Opioid market geography

Segments

Segments Covered in the Report

The North America opioid market has been segmented on the basis of

Products

  • Codeine
  • Extended-release/Long-acting
  • Immediate-release/Short-acting
  • Oxycodone
  • Hydrocodone
  • Morphine
  • Fentanyl
  • Hydroxymorphone
  • Propoxyphene
  • Oxymorphone
  • Methadone
  • Buprenorphine
  • Tapentadol

Applications

  • Cancer Pain
  • Pain Relief
  • Post-operative Pain Management
  • Orthopedic
  • Low Back Pain
  • Anesthesia
  • Fibromyalgia
  • Neuropathic Pain
  • Cough Suppression
  • De-addiction
  • Diarrhoea Suppression

Geography

  • The US
  • Canada

Key Players

  • Allergan Plc (Actavis)
  • Purdue Pharma L.P.
  • Pfizer, Inc.
  • Egalet Corp.
  • Janssen Pharmaceuticals, Inc.

Competitive Landscape

Key players competing in the North America opioid market are Allergan Plc (Actavis); Purdue Pharma L.P.; Pfizer, Inc.; Egalet Corp.; and Janssen Pharmaceuticals, Inc. The main market players are continuously engaged in various market expansion activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations to enhance their market share. For instance, Roxane laboratories, Inc. and Boehringer Ingelheim Roxane Inc. were acquired by Hikma Pharmaceuticals Plc in March 2016 to expand its business operations.

North America Opioid market keyplayers

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Opioid Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Opioid Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Opioid Market - Supply Chain
  4.5. Global Opioid Market Forecast
     4.5.1. Opioid Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Opioid Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Opioid Market Absolute $ Opportunity
5. Global Opioid Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Opioid Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Opioid Demand Share Forecast, 2019-2026
6. North America Opioid Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Opioid Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Opioid Demand Share Forecast, 2019-2026
7. Latin America Opioid Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Opioid Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Opioid Demand Share Forecast, 2019-2026
8. Europe Opioid Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Opioid Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Opioid Demand Share Forecast, 2019-2026
9. Asia Pacific Opioid Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Opioid Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Opioid Demand Share Forecast, 2019-2026
10. Middle East & Africa Opioid Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Opioid Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Opioid Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Opioid Market: Market Share Analysis
  11.2. Opioid Distributors and Customers
  11.3. Opioid Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Allergan Plc (Actavis)
     11.4.2. Purdue Pharma L.P.
     11.4.3. Pfizer, Inc.
     11.4.4. Egalet Corp.
     11.4.5. Janssen Pharmaceuticals, Inc.

Segments Covered in the Report

The North America opioid market has been segmented on the basis of

Products

  • Codeine
  • Extended-release/Long-acting
  • Immediate-release/Short-acting
  • Oxycodone
  • Hydrocodone
  • Morphine
  • Fentanyl
  • Hydroxymorphone
  • Propoxyphene
  • Oxymorphone
  • Methadone
  • Buprenorphine
  • Tapentadol

Applications

  • Cancer Pain
  • Pain Relief
  • Post-operative Pain Management
  • Orthopedic
  • Low Back Pain
  • Anesthesia
  • Fibromyalgia
  • Neuropathic Pain
  • Cough Suppression
  • De-addiction
  • Diarrhoea Suppression

Geography

  • The US
  • Canada

Key Players

  • Allergan Plc (Actavis)
  • Purdue Pharma L.P.
  • Pfizer, Inc.
  • Egalet Corp.
  • Janssen Pharmaceuticals, Inc.

Key players competing in the North America opioid market are Allergan Plc (Actavis); Purdue Pharma L.P.; Pfizer, Inc.; Egalet Corp.; and Janssen Pharmaceuticals, Inc. The main market players are continuously engaged in various market expansion activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations to enhance their market share. For instance, Roxane laboratories, Inc. and Boehringer Ingelheim Roxane Inc. were acquired by Hikma Pharmaceuticals Plc in March 2016 to expand its business operations.

North America Opioid market keyplayers

Buy Report